Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME-Reference-Cited by-同舟云学术

Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

Published:2020-06-26 Issue:9 Volume:38 Page:1829-1840
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Böhm Michael,Fitchett David,Ofstad Anne Pernille,Brueckmann Martina,Kaspers Stefan,George Jyothis T.,Zwiener Isabella,Zinman Bernard,Wanner Christoph,Marx Nikolaus,Mancia Giuseppe,Anker Stefan D.,Mahfoud Felix

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference33 articles.

1. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012

2. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Cosentino;Eur Heart J,2019

3. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2013

4. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension;Tikkanen;Diabetes Care,2015

5. 24-Hour Blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA Study;Kario;Circulation,2019

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SGLT-2 inhibitors on acute kidney injury in patients with heart failure: a systematic review and meta-analysis;Diabetology & Metabolic Syndrome;2024-08-27

2. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

3. Empagliflozin in the treatment of heart failure;Future Cardiology;2024-04-25

4. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease;Circulation Research;2023-04-14

5. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease;Journal of Clinical Medicine;2023-04-12